A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

  • STATUS
    Recruiting
  • End date
    Jun 28, 2026
  • participants needed
    140
  • sponsor
    Theseus Pharmaceuticals
Updated on 4 October 2022
cancer
treatment regimen
bone marrow procedure
primary cancer
neuropathy
immunostimulants

Summary

This study will assess the safety, efficacy, and pharmacokinetics of THE-630 in participants with advanced gastrointestinal stromal tumors (GIST).

Description

The drug being tested in this study is called THE-630, an orally administered KIT tyrosine kinase inhibitor. The study will be conducted in two parts: a dose escalation phase, followed by an expansion phase. The patient population of the initial dose escalation phase (Phase 1) of the trial will include patients with unresectable or metastatic GIST. Patients must have disease progression on or be intolerant to imatinib therapy and have also received at least 1 of the following: sunitinib, regorafenib, ripretinib, or avapritinib. The primary objective of the dose escalation phase is to determine the safety profile of oral THE-630, including the dose limiting toxicities (DLTs), maximum tolerated dose (MTD), and the recommended phase 2 dose (RP2D).

Once a recommended dose has been determined in the escalation phase, the expansion phase (Phase 2) will enroll 3 cohorts of patients with unresectable or metastatic GIST defined by prior therapy:

  • Cohort 1: Patients with unresectable or metastatic GIST who have progressed on or are intolerant to imatinib, sunitinib, regorafenib and ripretinib (≥5th Line).
  • Cohort 2: Patients with unresectable or metastatic GIST who have progressed on or are intolerant to imatinib, sunitinib and 0-1 additional lines of therapy in the advanced/metastatic setting (3rd-4th Line).
  • Cohort 3: Patients with unresectable or metastatic GIST who have progressed on or are intolerant to imatinib (including in the adjuvant setting) and who have not received additional systemic therapy for advanced GIST (2nd Line).

The safety and tolerability of orally administered THE-630 will continue to be assessed in the expansion cohorts. However, the primary objective of the expansion component of the trial is to evaluate the anti-tumor activity of THE-630 in these GIST patient populations.

Details
Condition Gastrointestinal Stromal Tumors (GIST), Neoplasms, Connective Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type, Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasm, Digestive System Disease, Gastrointestinal Diseases
Treatment THE-630
Clinical Study IdentifierNCT05160168
SponsorTheseus Pharmaceuticals
Last Modified on4 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Male or female patient ≥ 18 years of age
For Dose Escalation Phase Cohorts (Phase 1)
Have histologically- or cytologically-confirmed unresectable or metastatic GIST
Have progressed on or are intolerant to imatinib therapy and have also received at least 1 of the following: sunitinib, regorafenib, ripretinib, or avapritinib
For Expansion Phase Cohorts (Phase 2)
Cohort 1
Have histologically- or cytologically confirmed unresectable or metastatic GIST
Have progressed on or are intolerant to imatinib, sunitinib, regorafenib and ripretinib
Cohort 2
Have histologically- or cytologically confirmed unresectable or metastatic GIST
Have progressed on or are intolerant to imatinib and sunitinib. Patients in this cohort are allowed to have received up to 1 additional line of therapy in the advanced/metastatic setting
Have histologically- or cytologically confirmed unresectable or metastatic GIST
Cohort 3
Have progressed on or are intolerant to imatinib (including in the adjuvant setting)
Have not received additional systemic therapy for advanced GIST
Have at least 1 measurable lesion as defined by modified RECIST 1.1
Have archival or new tumor biopsy tissue available to submit for mutational testing
Have Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2
Adequate renal, hepatic and bone marrow function as defined by the protocol
For female patients of childbearing potential, have a negative serum or urine beta human chorionic gonadotropin (β-hCG) pregnancy test within 7 days prior to the first dose of study drug
Note: female patients of nonchildbearing potential (postmenopausal; hysterectomy; bilateral salpingectomy; or bilateral oophorectomy) do not require a pregnancy test
Female patients of childbearing potential must agree to abstain from heterosexual
intercourse or use a highly effective form of contraception with their sexual
partners during the dosing period and for a period of at least 30 days after
the end of treatment. Male patients with partners of childbearing potential
must agree that they will abstain from heterosexual intercourse or use condoms
and their partners will use highly effective contraceptive methods during the
dosing period until at least 90 days after the last dose of study drug
All toxicities from prior therapy have resolved to ≤ grade 1 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0), or have resolved to baseline, at the time of first dose of study drug. Note: treatment-related grade >1 alopecia, treatment related grade 2 peripheral neuropathy, and treatment-related grade 2 hypothyroidism on a stable dose of thyroid hormone replacement therapy are allowed if deemed irreversible

Exclusion Criteria

Received systemic anticancer therapy (including cytotoxic chemotherapy, investigational agent, antineoplastic monoclonal antibodies, or immunotherapy) less than 5 half-lives or 14 days (whichever is shorter) prior to the first dose of study drug
Patients known to be both KIT and PDGFRA wild-type
Received radiotherapy within 14 days prior to the first dose of study drug
Major surgical procedure within 28 days of the first dose of study drug. Minor surgical procedures such as central venous catheter placement or minimally invasive biopsy are allowed
Have known untreated or active central nervous system metastases
-lead electrocardiogram (ECG) demonstrating QT interval corrected by Fridericia's formula (QTcF) >470 msec at screening, or history of long QTc syndrome
Have significant, uncontrolled, or active cardiovascular disease, including, but not restricted to
Myocardial infarction (MI) within 6 months prior to the first dose of study drug
Unstable angina within 6 months prior to first dose of study drug
Symptomatic congestive heart failure (New York Heart Association classes II-IV) within 6 months prior to first dose of study drug
Clinically significant, uncontrolled atrial arrhythmia (as determined by the Investigator)
Any history of ventricular arrhythmia
Cerebrovascular accident or transient ischemic attack within 6 months prior to first dose of study drug
Uncontrolled hypertension at study entry. Patients with hypertension should be under treatment on study entry to control blood pressure
Have an active uncontrolled infection, including, but not limited to, the requirement
for intravenous antibiotics
Any active bleeding excluding hemorrhoidal or gum bleeding
For patients with a known human immunodeficiency virus (HIV) infection, have CD4+ T-cell counts <350 cells/uL or history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection within the past 12 months. Patients with HIV infection should be on established antiretroviral therapy (ART) for at least 4 weeks and have an HIV viral load less than 400 copies/mL prior to enrollment
Has known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, as evidenced by detectable viral load (HBV-DNA or HCV-RNA, respectively). Risk of HBV reactivation should be considered in all patients and the need for anti-HBV prophylaxis should be carefully assessed. Patients with chronic HBV infection with history of active disease who meet the criteria for anti HBV therapy should be on a suppressive antiviral therapy to be eligible for enrollment. Patients who are HCV Ab positive but HCV RNA negative due to prior treatment or natural resolution are eligible. Patients on concurrent HCV treatment at the time of enrollment are allowed if HCV RNA negative
Pregnant or breastfeeding
Patients with prior or concurrent malignancies other than GIST are allowed, except in the case where, in the opinion of the Investigator, the natural history or treatment of the other malignancy has the potential to interfere with the safety or efficacy assessment of the study drug
Have any condition or illness that, in the opinion of the Investigator, might compromise patient safety or interfere with the evaluation of the safety of the drug
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note